Clinigen Group PLC Receives Buy Rating from Numis Securities Ltd (CLIN)
Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating reaffirmed by analysts at Numis Securities Ltd in a research report issued to clients and investors on Wednesday. They currently have a GBX 650 ($10.87) price objective on the stock. Numis Securities Ltd’s price target points to a potential upside of 61.42% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at N+1 Singer reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Wednesday. They now have a GBX 439 ($7.34) price target on the stock. Finally, analysts at Investec reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Thursday, July 24th. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of GBX 592.20 ($9.90).
Clinigen Group PLC (LON:CLIN) opened at 428.919 on Wednesday. Clinigen Group PLC has a 52-week low of GBX 354.92 and a 52-week high of GBX 690.00. The stock has a 50-day moving average of GBX 378.4 and a 200-day moving average of GBX 469.7.
Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.